Demographic information for participants is presented in Table 1. FPG was measured using the hexokinase method (Cobas C311 analyzer, Roche Diagnostics, Indianapolis, USA) from plasma samples in ...

Sir Brian Roche says there is a concern about the level of analysis given to Treaty "breaches". Photo / Marty Melville There are too many meetings in the public service, too many layers of ...

We explore the history of global pharmaceutical group Hoffmann-La Roche from where it first began, to its core structure and its focus for the future in personalised medicine. Roche was found in ...

Long-serving Roche chief executive Severin Schwan is stepping down, to be replaced next March by Thomas Schinecker, currently head of diagnostics at the Swiss group. Schwan (pictured above ...

If anything, the gap understates the gulf between the soft-spoken, beetle-browed Hoffmann, who is the great-grandson of Fritz Hoffmann-La Roche, founder of pharmaceuticals group Roche, and the ...

Roche (OTCQX:RHHBY) has received FDA clearance with a CLIA waiver for its cobas liat sexually transmitted infection, or STI, multiplex assay panels. The tests will be available exclusively in the U.S.

The prognostic test stratifies hospitalized women with hypertensive disorders of pregnancy into low- and high-risk categories for developing severe preeclampsia.

Navigate with Confidence This manual guides you through the process of setting up, using, and maintaining your new Cobas C311 User Manual with confidence. Operating Instructions for Beginners This ...

Greetings and welcome to the user manual for your newly updated Cobas C311 Manual. This manual is specifically designed to help you get the most out of your product by providing a thorough explanation ...

Roche has a big problem. With competition threatening some of its older and most lucrative biologic drugs, the Swiss pharmaceutical giant expects that, between 2023 and 2028, sales from these assets ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...